Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease
@article{Chen2005ClinicalPO, title={Clinical Pharmacology of Rasagiline: A Novel, Second‐Generation Propargylamine for the Treatment of Parkinson Disease}, author={J. Chen and D. Swope}, journal={The Journal of Clinical Pharmacology}, year={2005}, volume={45} }
Rasagiline is a novel second‐generation propargylamine that irreversibly and selectively inhibits monoamine oxidase type B (MAO‐B). For the management of Parkinson disease (PD), rasagiline is efficacious across the span of PD stages ranging from monotherapy in early disease to adjunctive treatment in patients with advancing disease and motor fluctuations. Rasagiline completely and selectively inhibits MAO‐B with a potency 5 to 10 times greater than selegiline. Unlike the prototype… CONTINUE READING
Topics from this paper
117 Citations
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
- Medicine
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
- 2006
- 49
Rasagiline in treatment of Parkinson’s disease
- Medicine
- Neuropsychiatric disease and treatment
- 2008
- 18
- PDF
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson’s Disease with Neuroprotective Potential
- Medicine
- Rambam Maimonides medical journal
- 2010
- 15
- PDF
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
- Chemistry, Medicine
- Progress in Neurobiology
- 2010
- 132
Role of rasagiline in treating Parkinson’s disease: Effect on disease progression
- Medicine
- Therapeutics and clinical risk management
- 2009
- 7
- Highly Influenced
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson’s disease
- Medicine
- Expert opinion on drug metabolism & toxicology
- 2014
- 10
Rasagiline: A Review of Its Use in the Treatment of Idiopathic Parkinson’s Disease
- Medicine
- CNS Drugs
- 2014
- 9
- Highly Influenced
- PDF
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
- Medicine
- Clinical therapeutics
- 2007
- 161
Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease
- Medicine
- Pharmacotherapy
- 2007
- 148
- PDF
Safety of rasagiline for the treatment of Parkinson's disease
- Medicine
- Expert opinion on drug safety
- 2011
- 25
References
SHOWING 1-10 OF 111 REFERENCES
The importance of propargylamine moiety in the anti‐ Parkinson drug rasagiline and its derivatives for MAPK‐ dependent amyloid precursor protein processing
- Chemistry, Medicine
- FASEB journal : official publication of the Federation of American Societies for Experimental Biology
- 2003
- 106
Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa
- Medicine
- Clinical neuropharmacology
- 2000
- 152
- Highly Influential
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline
- Medicine
- British journal of pharmacology
- 2004
- 40
Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B
- Chemistry, Medicine
- British journal of pharmacology
- 2001
- 285
- Highly Influential
Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes.
- Biology, Psychology
- Neurotoxicology and teratology
- 2002
- 149
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
- Chemistry, Medicine
- Journal of neuroscience research
- 2005
- 143
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline
- Medicine
- Neuroscience Letters
- 2004
- 144
Effect of lazabemide on the progression of disability in early Parkinson's disease
- Medicine
- Annals of neurology
- 1996
- 110